Investigation of the mechanism of hypertension caused by BTKi in the treatment of hematologic diseases
Authors:
Open Access
- 15 May 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1585061
Abstract
Bruton’s tyrosine kinase inhibitors (BTKis) have made substantial impacts on the treatment of B-cell malignancies like chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Therapeutic benefits aside, the clinical use of BTKis comes with several side effects, of which hypertension (HTN) is quite common and serious and of significant clinical concern. The present article will discuss the mechanisms by which the use of BTKis causes hypertension and outline strategies for managing the condition within the clinic. Studies indicate that using BTKis interferes with BTK’s central role within the B-cell receptor (BCR) signaling cascade and impacts multiple downstream signaling pathways like PI3K/Akt, MAPK, and NF-κB. These changes contribute to endothelial dysfunction, increased oxidative stress, and vascular constriction, all of which are implicated in the development of hypertension. Of special concern is that oxidative stress (OS) is directly related to decreased endothelial nitric oxide (NO) production, a finding that becomes particularly relevant during the initiation of BTKi therapy. Also, BTKis affect vascular development and tone regulation by activating the Notch and RhoA/ROCK pathways, leading to increased vasoconstriction and the advancement of hypertension. In light of the possibility that BTKi-induced hypertension might jeopardize treatment tolerability and patient outcomes, this review proposes a multimodal management of the condition, including careful monitoring of blood pressure, individualized antihypertensive treatment, and possible modifications of the dosing of BTKis. Future investigations should look into the specific molecular mechanisms underpinning the development of hypertension due to BTKis as well as the effects of various antihypertensive regimens on the improvement of the cardiovascular profile of affected individuals.Keywords
This publication has 249 references indexed in Scilit:
- Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicityCancer, 2023
- BTKi bonanza in CLL/SLL: Sorting out the differencesAmerican Journal of Hematology, 2023
- Calcium channel blockers versus other classes of drugs for hypertensionCochrane Database of Systematic Reviews, 2021
- The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphomaHematological Oncology, 2021
- Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaAmerican Journal of Hematology, 2019
- Endothelial Dysfunction and Hypertension2016
- Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignanciesClinical Pharmacology & Therapeutics, 2015
- Effect of Self-monitoring and Medication Self-titration on Systolic Blood Pressure in Hypertensive Patients at High Risk of Cardiovascular DiseaseJAMA, 2014
- Association of SLP-65 / BLNK with the B cell antigen receptor through a non-ITAM tyrosine of Ig-αEuropean Journal of Immunology, 2001
- Rho-Kinase Inhibitor Retards Migration and in Vivo Dissemination of Human Prostate Cancer CellsBiochemical and Biophysical Research Communications, 2000